


Tenet (THC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare is rated Buy, driven by robust Q2 results, margin expansion, and attractive valuation at 12.7x forward EPS. Hospital segment EBITDA margin surged to 18%, with adjusted EBITDA up 22.3% and EPS up 52.2%, supporting raised 2026 guidance. USPI remains a key growth lever, delivering a 39% EBITDA margin, though same-center surgical volumes declined; future upside depends on volume recovery.

In the most recent trading session, Tenet Healthcare (THC) closed at $269.13, indicating a -1.17% shift from the previous trading day.

Recently, Zacks.com users have been paying close attention to Tenet (THC). This makes it worthwhile to examine what the stock has in store.

CWA Asset Management Group LLC grew its stake in shares of Tenet Healthcare Corporation (NYSE: THC) by 8.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,209 shares of the company's stock after acquiring an additional 2,114 shares

First Citizens Bank and Trust Co. reduced its holdings in shares of Tenet Healthcare Corporation (NYSE: THC) by 58.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,224 shares of the company's stock after selling 4,586 shares during the quarter.